

Amendment to the Claims

Please amend claims 5, 8, 11 and 12 and add new claims 13-20 as shown below.

1. (Original) An examination method conducted for the administration of an anticancer drug targeting a tumor-associated factor receptor, in order to evaluate usefulness of treatment with the anticancer drug, comprising, in addition to the examination of the gene and/or the expressed product thereof of the receptor, the examination of the gene and/or the expressed product thereof of a substance interacting with the receptor on the surface of and/or within the cell membrane.
2. (Original) The examination method according to Claim 1, wherein the tumor-associated factor receptor is a cell growth factor receptor.
3. (Original) The examination method according to the Claim 2, wherein the cell growth factor receptor is an epidermal growth factor receptor or a receptor belonging to an epidermal growth factor receptor family.
4. (Original) The examination method according to Claim 3, wherein the receptor belonging to the epidermal growth factor receptor family is HER2/c-erbB-2.
5. (Currently Amended) The examination method according to ~~any one of Claims 1 to 4~~ Claim 1, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.

6. (Original) The examination method according to Claim 5, wherein the glycoprotein is a mucin.
7. (Original) The examination method according to Claim 6, wherein the mucin is mucin 4 (MUC4).
8. (Currently Amended) The examination method according to ~~any one of Claims 1 to 7~~ Claim 1, wherein the anticancer drug is an antibody to the receptor.
9. (Original) The examination method according to Claim 8, wherein the antibody is a humanized monoclonal antibody.
10. (Original) The examination method according to Claim 9, wherein the humanized monoclonal antibody is trastuzumab (HerceptinTM).
11. (Currently Amended) A reagent for use in the examination method according to ~~any one of Claims 1 to 10~~ Claim 1.
12. (Currently Amended) A reagent kit for use in the examination method according to ~~any one of Claims 1 to 10~~ Claim 1.

13. (New) The examination method according to Claim 2, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.
14. (New) The examination method according to Claim 3, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.
15. (New) The examination method according to Claim 4, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.
16. (New) The examination method according to Claim 2, wherein the anticancer drug is an antibody to the receptor.
17. (New) The examination method according to Claim 3, wherein the anticancer drug is an antibody to the receptor.
18. (New) The examination method according to Claim 4, wherein the anticancer drug is an antibody to the receptor.
19. (New) The examination method according to Claim 5, wherein the anticancer drug is an antibody to the receptor.
20. (New) The examination method according to Claim 6, wherein the anticancer drug is an antibody to the receptor.